Brief: Briacell And Imaginab Announce Collaboration To Evaluate Immunotherapy Imaging Technology In Advanced Breast Cancer
19/08/2021 13:17
Aug 19 (Reuters) - Briacell Therapeutics Corp BCT.V :
* BRIACELL AND IMAGINAB ANNOUNCE COLLABORATION TO EVALUATE
IMMUNOTHERAPY IMAGING TECHNOLOGY IN ADVANCED BREAST CANCER
* BRIACELL THERAPEUTICS - IMAGINAB WILL SUPPLY CLINICAL
DOSES OF
ITS MARKET LEADING CD8 IMMUNOPET TECHNOLOGY TO BRIACELL FOR USE
IN A STUDY
* BRIACELL THERAPEUTICS CORP - NO OTHER TERMS ARE DISCLOSED
Source text for Eikon: ID:nGNX28VnJQ
Further company coverage: BCT.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study